4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
| Revenue (Most Recent Fiscal Year) | $85.21M |
| Net Income (Most Recent Fiscal Year) | $-140.11M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.97 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.92 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -194.74% |
| Net Margin (Trailing 12 Months) | -194.74% |
| Return on Equity (Trailing 12 Months) | -41.33% |
| Return on Assets (Trailing 12 Months) | -35.90% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.05 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.38 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.42 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.63 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 55.24M |
| Free Float | 50.88M |
| Market Capitalization | $825.35M |
| Average Volume (Last 20 Days) | 1.12M |
| Beta (Past 60 Months) | 2.74 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.27% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |